Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...
One in five people will get cancer in their lifetime – almost everyone has been...
Prescient is focused on developing new therapies for cancers with unmet needs.
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...
Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, aggressive...
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a...
PTX-100 targets high-mortality cancers linked to RAS mutations.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.